| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 06/21/2007 | US20070141154 Antidiabetic formulation and method |
| 06/21/2007 | US20070141150 Pharmaceutical composition |
| 06/21/2007 | US20070141149 Controlled-release pharmaceutical formulation |
| 06/21/2007 | US20070141148 Neramexane MR matrix tablet |
| 06/21/2007 | US20070141147 Sequential release pharmaceutical formulations |
| 06/21/2007 | US20070141146 Novel compositions |
| 06/21/2007 | US20070141145 Hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same |
| 06/21/2007 | US20070141141 Pharmaceutical composition |
| 06/21/2007 | US20070141140 Semi-solid formulations for immediate release intended for the oral administration of drugs |
| 06/21/2007 | US20070141139 Composition for intestinal delivery |
| 06/21/2007 | US20070141138 Omega 3 fatty acid formulations |
| 06/21/2007 | US20070141137 Stable capsule preparation |
| 06/21/2007 | US20070141134 Shielded micelles for polynucleotide delivery |
| 06/21/2007 | US20070141132 Human growth hormone patch formulations |
| 06/21/2007 | US20070141129 Wound care product comprising a substance which inhibits the growth of bacteria in wounds |
| 06/21/2007 | US20070141123 Emulsions comprising non-esterified phytosterols in the aqueous phase |
| 06/21/2007 | US20070141122 Nutritional composition and method of manufacture |
| 06/21/2007 | US20070141118 Layered dosage form for a medicated tampon assembly |
| 06/21/2007 | US20070141117 Melt extrusion of a mixture of memantine and biodegradable glycolic acid-lactic acid copolymer to make a sustained release implant to last for one week; glaucoma and proliferative vitreoretinopathy |
| 06/21/2007 | US20070141109 Local Deliver of 17-Beta Estradiol for Preventing Vascular Intimal Hyperplasia and for Improving Vascular Endothelium Function after Vascular Injury |
| 06/21/2007 | US20070141102 Drug delivery system based on polyethylene vinylacetate copolymers |
| 06/21/2007 | US20070141093 an oil-in-water emulsion, a water-in-oil emulsion or micelle formulation selected from sebacate bis(paclitaxel-2'-yl) ester and sebacate bis(docetaxel-2'-yl) ester, used for for treating lung, mammary gland, colon or ovarian cancer |
| 06/21/2007 | US20070141092 Biguanide composition and method of treatment and prevention of viral infections |
| 06/21/2007 | US20070141091 Biguanide ointment and method of treatment and prevention of infections |
| 06/21/2007 | US20070141090 Microemulsion preparation of high concentration propofol for anesthetic uses |
| 06/21/2007 | US20070141089 Topical composition comprising terbinaf ine adn hydrocortisone |
| 06/21/2007 | US20070141088 Glucan-based vaccines |
| 06/21/2007 | US20070141086 Use of antibiotics as vaccine adjuvants |
| 06/21/2007 | US20070141074 Agents for the inhibition of virus replication through regulation of protein folding |
| 06/21/2007 | US20070141069 Method for use of IGF-binding protein for selective sensitization of target cells in vivo |
| 06/21/2007 | US20070141059 Use of cathepsin s inhibitors for treating an immune response caused by administration of a small molecule therapeutic or biologic |
| 06/21/2007 | US20070141038 Gene repair involving the induction of double-stranded DNA cleavage at a chromosomal target site |
| 06/21/2007 | US20070141028 Cancer gene therapeutic drug |
| 06/21/2007 | US20070141027 Non-lethal conditioning methods for conditioning a recipient for bone marrow transplantation |
| 06/21/2007 | US20070141022 Polymeric delivery agents and delivery agent compounds |
| 06/21/2007 | US20070141020 Use of biocompatible polymers for the preparation of a composition or a medical device |
| 06/21/2007 | US20070141018 Food composition comprising glucosamine |
| 06/21/2007 | US20070141014 Formulation assistants |
| 06/21/2007 | US20070141004 Topical administration carrier composition and therapeutic formulations comprising same |
| 06/21/2007 | US20070141000 e.g. L-Ascorbic acid-2-phosphoric acid-6-(2'-hexyldecanoate) sodium salt; collagen production accelerators; skin whitening; medical, pharmaceutical preparations, feeds, foods and agrochemicals; storage stability, |
| 06/21/2007 | US20070140999 Topical skin care composition containing refined peanut oil |
| 06/21/2007 | US20070140987 Promoting whole body health |
| 06/21/2007 | US20070140984 Functional powdery product |
| 06/21/2007 | US20070140983 Ion Exchange Resin Treated to Control Swelling |
| 06/21/2007 | US20070140982 Diuretic Aerosols and Methods of Making and Using Them |
| 06/21/2007 | US20070140981 Intranasal compositions |
| 06/21/2007 | US20070140980 Preparation of sterile aqueous suspensions comprising micronised crystalline active ingredients for inhalation |
| 06/21/2007 | US20070140978 Adrenergic complement inhaler |
| 06/21/2007 | US20070140977 Methods of transdermally administering an indole serotonin receptor agonist and transdermal compositions for use in the same |
| 06/21/2007 | US20070140975 Opioid formulations having reduced potential for abuse |
| 06/21/2007 | US20070140970 Cell targeting conjugates |
| 06/21/2007 | US20070140965 Methods to ameliorate and image angioplasty-induced vascular injury |
| 06/21/2007 | US20070138897 Dc motor |
| 06/21/2007 | DE60125036T2 Hydroxyformamidin-derivate und diese enthaltende medikamente Hydroxyformamidin derivatives and containing the same drug |
| 06/21/2007 | DE60121550T2 Pyrimidin-4-onderivat als LDL-PLA2 Inhibitor Pyrimidin-4-one derivative as LDL-PLA2 inhibitor |
| 06/21/2007 | DE102005060690A1 Salze von Clopidogrel mit Polyanionen und ihre Verwendung zur Herstellung pharmazeutischer Formulierungen Salts of clopidogrel with polyanions and their use for the preparation of pharmaceutical formulations |
| 06/21/2007 | DE102005060393A1 Pharmaceutical pellet, useful for the production of tablet, comprises a spherical active agent, preferably metroprololsuccinate, comprising core with smooth surface and a coat on the core, where the active agent release is pH-independent |
| 06/21/2007 | DE102005060377A1 Composition, useful for preparing compressed form, preferably tablets to treat senile dementia, preferably for preventing and alleviating Alzheimer's disease, comprises donepezil hydrochloride of polymorph form |
| 06/21/2007 | DE102005059602A1 Verfahren zur Mikronisierung Process for the micronization |
| 06/21/2007 | CA2808259A1 Polymorphs and amorphous forms of 5-amino-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-4-[(trifluoromethyl)sulfinyl]-1h-pyrazole-3-carbonitrile |
| 06/21/2007 | CA2808257A1 Polymorphs and amorphous forms of 5-amino-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-4-[(trifluoromethyl)sulfinyl]-1h-pyrazole-3-carbonitrile |
| 06/21/2007 | CA2667091A1 Method for correcting a lipid imbalance in a subject |
| 06/21/2007 | CA2637740A1 Fused pyrrole derivatives |
| 06/21/2007 | CA2635717A1 Crystalline forms of 1-benzoyl-4-[2[4-methoxy-7-(3-methyl-1h-1,2,4-triazol-1-yl)-1-[(phosphonooxy)methyl]-1h-pyrrolo[2,3-c]pyridin-3-yl]-1,2-dioxoethyl]-piperazine |
| 06/21/2007 | CA2634168A1 Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof |
| 06/21/2007 | CA2634166A1 Use of low-dose ladostigil for neuroprotection |
| 06/21/2007 | CA2634006A1 Pharmaceutical sustained release compositions comprising liothyronine or the sodium salt of liothyronine |
| 06/21/2007 | CA2634004A1 Dibenzene derivatives as calcium channel blockers |
| 06/21/2007 | CA2633978A1 Bioabsorbable implant of hyaluronic acid derivative for treatment of osteochondral and chondral defects |
| 06/21/2007 | CA2633957A1 Treatment of arthritis and other musculoskeletal disorders with crosslinked hyaluronic acid |
| 06/21/2007 | CA2633954A1 Meniscal implant of hyaluronic acid derivatives for treatment of meniscal defects |
| 06/21/2007 | CA2633909A1 Modified and pulsatile release pharmaceutical formulations of escitalopram |
| 06/21/2007 | CA2633908A1 Hydroxyquinoline derivatives useful for the treatment of tumors and cellular proliferation |
| 06/21/2007 | CA2633832A1 Diagnosis, prognosis and monitoring of disease progression of systemic lupus erythematosus through blood leukocyte microarray analysis |
| 06/21/2007 | CA2633829A1 Indolone compounds useful to treat cognitive impairment |
| 06/21/2007 | CA2633603A1 Pharmaceutical combination comprising nucleotide and nucleoside reverse transcriptase inhibitors (such as tenofovir and lamivudine) in different parts of the dosage unit |
| 06/21/2007 | CA2633569A1 N-(5-membered heteroaromatic ring)-amido anti-viral compounds |
| 06/21/2007 | CA2633543A1 Antitumour compounds |
| 06/21/2007 | CA2633541A1 N-(6-membered aromatic ring)-amido anti-viral compounds |
| 06/21/2007 | CA2633497A1 Use of polyunsaturated compounds as whitening agents |
| 06/21/2007 | CA2633489A1 Compositions and methods for treating dermatological conditions |
| 06/21/2007 | CA2633481A1 Preventive or therapeutic agent for acute renal failure |
| 06/21/2007 | CA2633417A1 Diaryl ureas for treating virus infections |
| 06/21/2007 | CA2633414A1 Diaryl urea for treating inflammatory skin. eye and/or ear diseases |
| 06/21/2007 | CA2633411A1 Diaryl ureas for treating inflammatory skin, eye and/or ear diseases |
| 06/21/2007 | CA2633400A1 Diaryl urea for treating virus infections |
| 06/21/2007 | CA2633374A1 Amine compound and use thereof for medical purposes |
| 06/21/2007 | CA2633372A1 Easily absorbed oral preparations of xanthine derivatives |
| 06/21/2007 | CA2633296A1 Method of detecting and reducing boar taint using nuclear receptors |
| 06/21/2007 | CA2633292A1 Use of soluble dietary fibres against muscle wasting |
| 06/21/2007 | CA2633268A1 Crystal form of atorvastatin hemi-calcium and processes for preparation thereof |
| 06/21/2007 | CA2633243A1 Azepinoindole derivatives as pharmaceutical agents |
| 06/21/2007 | CA2633211A1 Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or flt1 antagonist for treating cancer |
| 06/21/2007 | CA2633194A1 Nutritional supplement containing long-chain polyunsaturated fatty acids |
| 06/21/2007 | CA2633186A1 2-adamantylurea derivatives as selective 11.beta.-hsd1 inhibitors |
| 06/21/2007 | CA2633129A1 Alkylsulphonamide quinolines |
| 06/21/2007 | CA2633125A1 Adhesive pharmaceutical preparation containing bisoprolol |
| 06/21/2007 | CA2633093A1 Mglur1 antagonists as therapeutic agents |
| 06/21/2007 | CA2633063A1 Cell penetrating peptide conjugates for delivering of nucleic acids intocells |
| 06/21/2007 | CA2633035A1 Kinase inhibitors and their uses |